Loading...
XNAS
IPHA
Market cap170mUSD
Jul 09, Last price  
1.79USD
1D
-2.72%
1Q
26.95%
IPO
-70.85%
Name

Innate Pharma SA

Chart & Performance

D1W1MN
XNAS:IPHA chart
P/E
—
P/S
52.74
EPS
—
Div Yield, %
—
Shrs. gr., 5y
2.52%
Rev. gr., 5y
-47.48%
Revenues
3m
-77.92%
6,195,00014,290,00012,924,0007,716,0004,320,00011,740,00010,377,00012,469,000907,00017,906,00056,160,00032,631,00079,892,00068,973,00069,773,00012,112,00057,674,00051,901,00012,621,0002,787,000
Net income
-49m
L-0.59%
-6,042,000-8,918,000-9,852,000-14,626,000-13,658,000-6,980,000-3,199,000-2,892,000-19,647,000-6,706,00012,640,000-48,385,0003,049,000-20,759,000-63,984,000-52,809,000-58,103,000-7,570,000-49,471,000-49,177,000
CFO
-33m
L+372.14%
360,000-9,282,000-14,741,000-5,936,000-13,449,00012,986,000-10,475,000-10,967,000-18,134,000207,912,000-36,851,000-48,060,000-32,531,00034,924,000-51,807,000-58,457,000-19,154,000-32,558,000-6,896,000-32,559,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only
Add note

Profile

Innate Pharma S.A., a biotechnology firm based in Marseille, France, operates globally, focusing on the discovery, advancement, and commercialization of innovative antibody-based therapies, primarily targeting various oncological conditions. The company's clinical pipeline includes several promising candidates: Lacutamab (IPH4102): An anti-KIR3DL2 antibody currently undergoing Phase II clinical evaluation for cutaneous T-cell and peripheral T-cell lymphoma, as well as refractory Sézary syndrome. Monalizumab: An immune checkpoint inhibitor that has progressed to Phase III clinical trials, being investigated for its potential in treating advanced solid tumors, notably colorectal, lung, and head and neck cancers. Avdoralimab (IPH5401): A monoclonal antibody designed to block C5a binding to C5aR1. This compound is in Phase II clinical assessment for a range of inflammatory conditions, including COVID-19, bullous pemphigoid, and chronic spontaneous urticaria. IPH5201: A blocking antibody in Phase I trials, aimed at the CD39 immunosuppressive pathway. IPH5301: An anti-CD73 antibody targeting the immunosuppressive adenosine pathway to enhance anti-tumor immunity. IPH6101: An NKp46-based NK cell engager, intended for the development and assessment of up to two bispecific NK cell engagers. Beyond its clinical programs, Innate Pharma maintains an active preclinical research effort, featuring candidates such as IPH43 (an anti-MICA/B antibody-drug conjugate), an Anti-Siglec-9 antibody program, IPH65 (a proprietary tetraspecific antibody), IPH25 (a checkpoint inhibitor), and the IPH62 and IPH64 programs. To support its development and market reach, Innate Pharma has established strategic alliances and licensing agreements with major pharmaceutical companies, including AstraZeneca, Novo Nordisk A/S, Sanofi, and Orega Biotech. Additionally, it holds a co-development and license agreement with MedImmune Limited. The company was founded in 1999 and continues to operate from its headquarters in Marseille, France.
URL
https://www.innate-pharma.com/
IPO date
Oct 31, 2006
Employees
211
Domiciled in
FR
Incorporated in
FR

Valuation

Title
EUR in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT